The article presents the estimation of indirect costs of chronic N18 kidney disease in Poland.
Research methods: The presented estimates were based on the human capital method. They concern the costs of absenteeism, presenteeism, informal care, permanent or temporary incapacity to work and deaths.
Results: The total indirect cost of chronic renal failure was 281,134,988,528.50 PLN.
Conclusions: The indirect costs of chronic kidney disease in Poland are high, especially in terms of presenteeism. This result is consistent with the data obtained in other countries. Building cost awareness and enabling patients to be professionally active with flexible work schedules seem to be particularly important. The availability of more accurate data would allow for more accurate estimates of indirect costs of CKD and other chronic diseases in the future.

chronic kidney disease, cost analysis, indirect costs

Myśliwiec, M. (2017). Przewlekła choroba nerek [Chronic kidney disease]. W P. Gajewski and A. Szczeklik, Interna Szczeklika 2017 (p. 1532). Kraków: Medycyna Praktyczna.

Group, K. D. (2012). KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International, 1-150.

Myśliwiec , M. (2017). Przewlekła choroba nerek [Chronic kidney disease]. W P. Gajewski and A. Szczeklik, Interna Szczeklika 2017 (pp. 1532-1543). Medycyna Praktyczna.

Rutkowski, B. (2013). Przewlekła choroba nerek - dziesięć lat w praktyce i teorii [Chronic kidney disease – ten years in practice and theory]. Forum Nefrologiczne, 63-70.

Myślwiec, M. (2017). Przewlekła choroba nerek [Chronic kidney disease]. W P. Gajewski and A. Szczeklik, Interna Szczeklika (p. 543). Medycyna Praktyczna

Portal Statystyczy ZUS [ZUS Statistical Portal] [access date 14.12.2018]; www.psz.zus.pl.

Hermanowski, T. (2013). Szacowanie kosztów społecznych choroby i wpływu stanu zdrowia na aktywność zawodową i wydajność pracy [Estimation of the social costs of the disease and the impact of the health condition on professional activity and work efficiency]. Wolters Kluwer: Warsaw.

Eriksson, D., Karlsson, L., Eklund, O., Dieperink, H., Honkanen, E., Melin, J., . . . Lundberg, J. (2017). Real-world costs of autosomal dominant polycystic kidney disease in the Nordics. BMC Health Services Research.

Turchetti, G., Bellelli, S., Amato, M., Bianchi, S., Conti, P., Cupisti, A., . . . Pizzarelli, F. (2017). The social cost of chronic kidney disease in Italy. The European Journal of Health Economics.

Statistics Poland [access date 14.12.2018]; www.stat.gov.pl.

National Institute of Diabetes and Digestive and Kidney Diseases – NIH [data dostępu 14.12.2018]; www.niddk.nih.gov.

The 2050 Ageing Report - Underlying Assumptions and Projection Methodologies, European Economy 8/2014.

Atkins, R. (2005). The epidemiology of chronic kidney disease. Kidney International, 14-18.

American Association of Kidney Patients [data dostępu 14.12.2018]; www.aakp.org.

Kidney Works [access date 14.12.2018]; www.kidneyworks.org

Levey, A. and Coresh, J. (2002). Clinical Practice Guidelines for Chronic Kidney Disease: evaluation, classification and stratification. National Kidney Foundation.

The Medical Education Institute (MEI), and American Association of Kidney Patients (AAKP). (2017). A job retention program for people with chronic kidney disease (CKD). USA.

McQuoid, J., Welsh, J., Strazdins, L., Griffin, A. and Banwell, C. (2015). Integrating paid work and chronic illness in daily life: A space-time approach to understanding the challenges. Health and Place, 83-91.

Jha, V., Garcia-Garcia, G., Iseki, K., Li, Z., Naicker, S., Plattner, B., . . . Yang, C. (2013). Chronic kidney disease: global dimension and perspective. The Lancet, 260-272.

Jha, V. i Modi, G. (2018). Getting to know the enemy better—the global burden of chronic kidney disease. Kidney International , 462-464.

Sullvian, S. (2007). Employer challenges with the chronic kidney disease population. Journal of Managed Care & Specialty Pharmacy, 19-21.

Golestaneh, L., Alvarez, P., Reaven, N., Funk, S., McGaughey, K., Romero, A., . . . Onuigbo, M. (2017). All-cause costs increase exponentially with increased chronic kidney disease stage. The American Journal of Managed Care, 163-172

Levin, A., Tonelli, M., Bonventre, J., Coresh, J., Donner, J.-A., Fogo, A., . . . Eckardt, K.-U. (2017). Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. The Lancet, 1888-1917.

Eknoyan, G., Lamiere, N., Barsoum, R., Eckardt, K., Levin, A., Levin, N., . . . Wang , H. (2004). The burden of kidney disease: improving global outcomes. Kidney International, 1310-1314.